Outcomes | Anticipated absolute effects*(95% CI) | Relative effect(95% CI) | № of participants (studies) | Certainty of the evidence(GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with galcanezumab | |||||
Reduction in migraine daysfollow up: 6 months | The mean reduction in migraine days was − 2.6 days | The mean reduction in migraine days in the intervention group was 1.9 days fewer (2.3 fewer to 1.4 fewer) | – | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 240 mg results in reduction in migraine days compared with placebo. |
Reduction in use of acute attack medication follow up: 6 months | The mean reduction in use of acute attack medication was − 2.1 days | The mean reduction in use of acute attack medication in the intervention group was 1.7 days fewer (1.9 fewer to 1.4 fewer) | – | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 240 mg results in reduction in use of attack medication compared with placebo. |
Improvement in functional MSQ RFR score follow up: 6 months | The mean improvement in functional MSQ RFR score was 22.2 points | The mean improvement in functional MSQ RFR score in the intervention group was 7.3 points higher (5.6 higher to 9.1 higher) | – | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 240 mg results in improvement in functional MSQ RFR score compared with placebo. |
At least 50% reduction in days of migrainefollow up: 6 months | 372 per 1000 | 586 per 1000(522 to 658) | RR 1.5738(1.4013 to 1.7675) | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 240 mg results in at least 50% reduction of days of migraine compared with placebo. |
Serious adverse events follow up: 6 months | 11 per 1000 | 16 per 1000(6 to 41) | RR 1.3953(0.5347 to 3.6413) | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 240 mg results in a small possibly unimportant effect in serious adverse events occurrence compared with placebo. |
Mortality follow up: 6 months | 0 per 1000 | 0 per 1000(0 to 0) | not estimable | 1330(2 RCT) | No deaths occurred during the double-blind treatment phase of the trial. |